Guardant Health's 15min chart sees Bollinger Bands narrowing, KDJ death cross triggered.

According to Guardant Health's 15-minute chart, a narrowing of Bollinger Bands and a KDJ Death Cross occurred on September 5, 2025 at 14:45. This suggests a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, with potential for further downward movement.

Guardant Health (NASDAQ: GH) has been a focus of investor attention recently, with several analysts updating their price targets and ratings following the company's latest financial and clinical results. The healthcare company, which specializes in liquid biopsy technology, has shown strong revenue growth and positive clinical validation for its Shield blood test algorithm.

Analyst Reactions

BTIG, an investment firm, raised its price target for Guardant Health to $70 from $65, maintaining a Buy rating. The firm cited improvements in the Shield test's sensitivity and specificity as a significant advancement, reinforcing Guardant's leadership in liquid biopsy technology [1]. Despite this positive outlook, the stock experienced a 9% drop following the announcement, suggesting that investors may be misinterpreting the data.

Scotiabank also raised its price target to $60, maintaining a Sector Outperform rating. The bank noted that Guardant Health's second-quarter results exceeded expectations, prompting management to revise its full-year revenue growth guidance to 24-25% year-over-year [1].

Raymond James maintained its Outperform rating with a $61 price target, observing that the Shield V2 algorithm update showed less improvement than initially anticipated. Similarly, Evercore ISI reiterated an Outperform rating and a $60 price target, noting that the results from the ECLIPSE study were in line with the previous version [1].

Technical Indicators

According to Guardant Health's 15-minute chart, a narrowing of Bollinger Bands and a KDJ Death Cross occurred on September 5, 2025, at 14:45. This suggests a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, with potential for further downward movement.

Conclusion

Guardant Health's recent developments, including positive clinical validation for its Shield blood test algorithm and improved financial results, have generated interest from major firms. However, the stock's price has been volatile, with analysts expressing confusion about the stock's recent performance. Technical indicators also suggest a potential downward trend in the stock's momentum. Investors should closely monitor these developments and consider the broader market conditions when making investment decisions.

References

[1] https://www.investing.com/news/analyst-ratings/guardant-health-stock-price-target-raised-to-70-from-65-at-btig-93CH-4225057